Aim: Recombinant human thyroid-stimulating hormone (rhTSH) recently was approved as
an alternative to thyroid hormone withholding (THW) to elevate TSH for thyroid remnant …

Introduction Patients with differentiated thyroid cancer (DTC) are treated with (near)-total
thyroidectomy followed by remnant ablation. Optimal radioiodine-131 (131I) uptake is …

Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly
performed in the management of patients with differentiated thyroid cancer. Although many …

The effects of low-activity versus high-activity radioiodine regimens in thyroid remnant
ablation for patients with differentiated thyroid carcinoma (DTC) under recombinant human …

Previous studies demonstrated that preparation with recombinant human thyroid-stimulating
hormone (rhTSH) for thyroid remnant ablation results in lower extrathyroidal radiation …

Background: No long-term follow-up data are available for differentiated thyroid carcinoma
(DTC) patients prepared with either exogenous or endogenous TSH and treated with low …

Objective Remnant thyroid ablation is crucial in the management of patients with
differentiated thyroid cancer. However, the optimal dose of radioactive 131 I for ablation is …

Objectives We sought to empirically compare treatment room length-of-stay and patient
throughput for recombinant human thyroid-stimulating hormone (rhTSH)-aided thyroid …

Objectives Radioiodine ablation of thyroid tissue remains the cornerstone of treatment for
patients with differentiated thyroid carcinoma after thyroidectomy. Selecting an optimal dose …

To supplement limited relevant literature, we retrospectively compared ablation and disease
outcomes in high‐risk differentiated thyroid carcinoma (DTC) patients undergoing …